Related Experiment Video
Updated: Jun 8, 2026
07:17
Production and Detection of Reactive Oxygen Species (ROS) in Cancers
Published on: November 21, 2011
Targeting oxidative stress in cancer
Matthew W Lawless1, Kenneth J O'Byrne, Steven G Gray
1Mater Misericordiae University Hospital, University College Dublin, Centre for Liver Disease, Dublin, Ireland.
Expert Opinion on Therapeutic Targets
|October 15, 2010
Summary
Targeting histone deacetylases (HDACs) offers a promising therapeutic strategy for managing oxidative stress in various cancers. This approach leverages epigenetic mechanisms to combat cancer progression linked to cellular imbalances in reactive oxygen species (ROS).
Area of Science:
- Molecular Biology
- Cancer Research
- Epigenetics
Background:
- Reactive oxygen species (ROS) are natural metabolic by-products with crucial cellular roles.
- An imbalance between ROS formation and removal leads to oxidative stress, implicated in diseases like cancer.
- Histone deacetylases (HDACs) are key regulators of cellular responses to oxidative stress.
Purpose of the Study:
- To explore the therapeutic potential of targeting HDACs in the context of oxidative stress in cancer.
- To review the role of aberrant HDAC regulation in cancer progression.
- To examine specific cancer types, including COPD, NSCLC, and HCC, as examples.
Main Methods:
- Literature review focusing on HDACs and oxidative stress pathways in cancer.
- Analysis of the role of epigenetic mechanisms in cancer pathogenesis.
- Case study approach using COPD, NSCLC, and HCC to illustrate therapeutic possibilities.
Main Results:
- Aberrant regulation of oxidative stress pathways by HDACs is linked to cancer progression.
- Targeting HDACs presents a potential therapeutic strategy for oxidative stress-related cancers.
- Epigenetic modulation offers a novel approach to cancer treatment.
Conclusions:
- Epigenetic mechanisms, specifically targeting HDACs, represent a promising new therapeutic avenue.
- Modulating HDACs can help restore cellular balance in oxidative stress conditions relevant to cancer.
- This strategy holds potential for treating cancers such as NSCLC and HCC.
Related Concept Videos
01:46Electron Transport Chain: Complex I and II
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...